De novo FUS P525L mutation in Juvenile amyotrophic lateral sclerosis with dysphonia and diplopia
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 8, 2016
- Accepted in final form January 27, 2016
- First Published March 10, 2016.
Author Disclosures
- Claire S. Leblond, PhD*,
- Alina Webber, MD, MSc*,
- Ziv Gan-Or, MD, PhD,
- Fraser Moore, MD,
- Alain Dagher, MD, PhD,
- Patrick A. Dion, PhD and
- Guy A. Rouleau, MD, PhD
- Claire S. Leblond, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Tim E. No?l fellowship from ALS Canada, postdoctoral fellow, 2014-2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alina Webber, MD, MSc*,
Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ziv Gan-Or, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Canadian Institute of Health Research, Post-doctoral fellowship, post-doctoral fellow, 2014-2016
(1) McGill University
(1) Michael J. Fox Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Fraser Moore, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Participated in clinical trial sponsored by Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alain Dagher, MD, PhD,
NONE
NONE
NONE
Neuroimage, Editor, 2013-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Canadian Institutes for Health Research, PI, 1997-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patrick A. Dion, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Guy A. Rouleau, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) CIHR Foundation Scheme (FDN-143260); 07/2015 to 06/2022; 708,381$/year. Genetic & Biological Studies of Brain Disorders. Role: Principal Applicant (2) ALS Society of Canada, 09/2013 to 08/2015. Assessment of somatic mutations and repeat instability in known ALS genes. Role: Principal Applicant. (3) ALS Association (OJ3X54), 08/2012 to 07/2015. Characterization of C9ORF72 expansion stability in ALS/FTD patients. Role: Principal Applicant.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Human Genetics (C.S.L., Z.G.-O.), Montreal Neurological Institute and Hospital (C.S.L., A.W., Z.G.-O., F.M., A.D., P.A.D., G.A.R.), and Department of Neurology and Neurosurgery (A.W., F.M., A.D., P.A.D., G.A.R.), McGill University, Montreal, Quebec, Canada.
- Correspondence to Dr. Rouleau: guy.rouleau{at}mcgill.ca
Article usage
Cited By...
Letters: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.